Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sagimet Biosciences Inc. - Series A Common Stock (NQ: SGMT ) 2.820 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Sagimet Biosciences Inc. - Series A Common Stock < Previous 1 2 3 Next > Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit September 12, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Sagimet Biosciences to Participate in Two Upcoming Investor Conferences September 04, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire SGMT Stock Earnings: Sagimet Biosciences Beats EPS for Q2 2024 August 14, 2024 SGMT stock results show that Sagimet Biosciences beat analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates August 14, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors August 01, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat June 10, 2024 Call scheduled on Thursday, June 13, 2024 at 9.30 AM PT / 12:30 PM ET From Sagimet Biosciences Inc. Via GlobeNewswire What's Going On With Sagimet Biosciences Stock On Thursday? June 06, 2024 Sagimet Biosciences shared promising data from its FASCINATE-2 Phase 2b trial of denifanstat at the EASL Congress. Via Benzinga Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024 June 06, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday? June 05, 2024 Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment.... Via Benzinga Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday May 16, 2024 Via Benzinga Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024 May 16, 2024 Dr. Scott Friedman to present unmet need in MASH and discuss Sagimet’s topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH From Sagimet Biosciences Inc. Via GlobeNewswire SGMT Stock Earnings: Sagimet Biosciences Beats EPS for Q1 2024 May 15, 2024 SGMT stock results show that Sagimet Biosciences beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates May 15, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024 May 07, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer May 06, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024 April 22, 2024 Sagimet announced positive topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH in January 2024 and plans to initiate Phase 3 trial in the second half of 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat March 27, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Monday's Intraday Session March 25, 2024 Via Benzinga Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session March 25, 2024 Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news. Via Benzinga Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors March 25, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates March 25, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy? March 17, 2024 Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while. Via The Motley Fool Sagimet Biosciences to Participate in Two Upcoming Investor Conferences February 29, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Friday's After-Market Session February 16, 2024 Via Benzinga Why FMC Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session February 06, 2024 Shares of FMC Corporation (NYSE: FMC) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter results. Via Benzinga 12 Health Care Stocks Moving In Tuesday's Intraday Session February 06, 2024 Via Benzinga Week In Review: Arrivent BioPharma Raises $175 Million In IPO For In-Licensings From China January 27, 2024 ArriVent BioPharma priced its upsized Nasdaq IPO at $18 dollars per share, raising $175 million. The company’s stated goal is to find promising novel assets from China and other countries, which it... Via Talk Markets Topics Initial Public Offering Exposures Securities Market Why Intel Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session January 26, 2024 Shares of Intel Corporation (NASDAQ: INTC) fell sharply during Friday’s session. Intel reported upbeat results for its fourth quarter, but issued a weak forecast for the first quarter. Via Benzinga 12 Health Care Stocks Moving In Friday's Pre-Market Session January 26, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday January 26, 2024 Pre-market stock movers are worth checking out on Friday as we get into all of the biggest news affecting shares this morning! Via InvestorPlace < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.